{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T21:41:28Z","timestamp":1788903688718,"version":"build-2803163510"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":54,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-16084-1","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T04:15:33Z","timestamp":1778040933000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Immunotherapy combined with chemotherapy as first-line treatment for HER2-negative advanced gastric or gastroesophageal junction cancer: systematic review and Bayesian network meta-analysis based on specific PD-L1 expression levels"],"prefix":"10.1186","volume":"26","author":[{"given":"Wen","family":"Yi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalima","family":"Muhetaer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longhai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leiyu","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengcheng","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhetaibaier","family":"Hairoula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,6]]},"reference":[{"issue":"6","key":"16084_CR1","first-page":"394","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424.","journal-title":"CA Cancer J Clin"},{"key":"16084_CR2","doi-asserted-by":"publisher","first-page":"831207","DOI":"10.3389\/fonc.2022.831207","volume":"12","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, Liu Z, Chen Z. Comparison of Treatment Efficacy and Survival Outcomes Between Asian and Western Patients With Unresectable Gastric or Gastro-Esophageal Adenocarcinoma: A Systematic Review and Meta-Analysis. Front Oncol. 2022;12:831207.","journal-title":"Front Oncol"},{"issue":"7517","key":"16084_CR3","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nature13480","volume":"513","author":"AJ Bass","year":"2014","unstructured":"Bass AJ, Thorsson V, Shmulevich I, Reynolds SM, Miller M, Bernard B, et al. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513(7517):202\u20139.","journal-title":"Nature"},{"issue":"10","key":"16084_CR4","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","volume":"33","author":"F Lordick","year":"2022","unstructured":"Lordick F, Carneiro F, Cascinu S, Fleitas T, Haustermans K, Piessen G, et al. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(10):1005\u201320.","journal-title":"Ann Oncol"},{"issue":"1","key":"16084_CR5","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1093\/annonc\/mdy502","volume":"30","author":"K Muro","year":"2019","unstructured":"Muro K, Van Cutsem E, Narita Y, Pentheroudakis G, Baba E, Li J, et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. Ann Oncol. 2019;30(1):19\u201333.","journal-title":"Ann Oncol"},{"issue":"suppl 5","key":"16084_CR6","doi-asserted-by":"publisher","first-page":"v38","DOI":"10.1093\/annonc\/mdw350","volume":"27","author":"EC Smyth","year":"2016","unstructured":"Smyth EC, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v38\u201349.","journal-title":"Ann Oncol"},{"issue":"3","key":"16084_CR7","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s10120-016-0631-3","volume":"20","author":"A Kawazoe","year":"2017","unstructured":"Kawazoe A, Kuwata T, Kuboki Y, Shitara K, Nagatsuma AK, Aizawa M, et al. Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients. Gastric Cancer. 2017;20(3):407\u201315.","journal-title":"Gastric Cancer"},{"issue":"5","key":"16084_CR8","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1158\/2326-6066.CIR-15-0064","volume":"3","author":"LA Emens","year":"2015","unstructured":"Emens LA, Middleton G. The interplay of immunotherapy and chemotherapy: harnessing potential synergies. Cancer Immunol Res. 2015;3(5):436\u201343.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"16084_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.21037\/jgo-20-599","volume":"12","author":"D Shen","year":"2021","unstructured":"Shen D, Chen Q, Wu J, Li J, Tao K, Jiang Y. The safety and efficacy of neoadjuvant PD-1 inhibitor with chemotherapy for locally advanced esophageal squamous cell carcinoma. J Gastrointest Oncol. 2021;12(1):1\u201310.","journal-title":"J Gastrointest Oncol"},{"issue":"10294","key":"16084_CR10","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet (London England). 2021;398(10294):27\u201340.","journal-title":"Lancet (London England)"},{"issue":"5","key":"16084_CR11","doi-asserted-by":"publisher","first-page":"e180013","DOI":"10.1001\/jamaoncol.2018.0013","volume":"4","author":"CS Fuchs","year":"2018","unstructured":"Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, et al. Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. JAMA Oncol. 2018;4(5):e180013.","journal-title":"JAMA Oncol"},{"issue":"10142","key":"16084_CR12","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0140-6736(18)31257-1","volume":"392","author":"K Shitara","year":"2018","unstructured":"Shitara K, \u00d6zg\u00fcro\u011flu M, Bang YJ, Di Bartolomeo M, Mandal\u00e0 M, Ryu MH, et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet (London England). 2018;392(10142):123\u201333.","journal-title":"Lancet (London England)"},{"issue":"10","key":"16084_CR13","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1001\/jamaoncol.2020.3370","volume":"6","author":"K Shitara","year":"2020","unstructured":"Shitara K, Van Cutsem E, Bang YJ, Fuchs C, Wyrwicz L, Lee KW, et al. Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020;6(10):1571\u201380.","journal-title":"JAMA Oncol"},{"issue":"21","key":"16084_CR14","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1001\/jama.2023.19918","volume":"330","author":"J Xu","year":"2023","unstructured":"Xu J, Jiang H, Pan Y, Gu K, Cang S, Han L, et al. Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer: The ORIENT-16 Randomized Clinical Trial. JAMA. 2023;330(21):2064\u201374.","journal-title":"JAMA"},{"issue":"4","key":"16084_CR15","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1038\/s41591-024-03450-4","volume":"31","author":"L Shen","year":"2025","unstructured":"Shen L, Zhang Y, Li Z, Zhang X, Gao X, Liu B, et al. First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial. Nat Med. 2025;31(4):1163\u201370.","journal-title":"Nat Med"},{"key":"16084_CR16","doi-asserted-by":"publisher","first-page":"964442","DOI":"10.3389\/fimmu.2022.964442","volume":"13","author":"Q Tang","year":"2022","unstructured":"Tang Q, Chen Y, Li X, Long S, Shi Y, Yu Y, et al. The role of PD-1\/PD-L1 and application of immune-checkpoint inhibitors in human cancers. Front Immunol. 2022;13:964442.","journal-title":"Front Immunol"},{"issue":"11","key":"16084_CR17","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162(11):777\u201384.","journal-title":"Ann Intern Med"},{"key":"16084_CR18","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s11739-016-1583-7","volume":"12","author":"B Rouse","year":"2017","unstructured":"Rouse B, Chaimani A, Li T. Network meta-analysis: an introduction for clinicians. Intern Emerg Med. 2017;12:103\u201311.","journal-title":"Intern Emerg Med"},{"key":"16084_CR19","doi-asserted-by":"crossref","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised Trials. BMJ. 2019;366:l4898.","DOI":"10.1136\/bmj.l4898"},{"issue":"6","key":"16084_CR20","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1007\/s10120-024-01535-0","volume":"27","author":"N Boku","year":"2024","unstructured":"Boku N, Omori T, Shitara K, Sakuramoto S, Yamaguchi K, Kato K, et al. Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric\/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 trial. Gastric cancer: official J Int Gastric Cancer Association Japanese Gastric Cancer Association. 2024;27(6):1287\u2013301.","journal-title":"Gastric cancer: official J Int Gastric Cancer Association Japanese Gastric Cancer Association"},{"issue":"11","key":"16084_CR21","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","volume":"24","author":"SY Rha","year":"2023","unstructured":"Rha SY, Oh DY, Ya\u00f1ez P, Bai Y, Ryu MH, Lee J, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24(11):1181\u201395.","journal-title":"Lancet Oncol"},{"key":"16084_CR22","first-page":"e078876","volume":"385","author":"MZ Qiu","year":"2024","unstructured":"Qiu MZ, Oh DY, Kato K, Arkenau T, Tabernero J, Correa MC, et al. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial. BMJ (Clinical Res ed). 2024;385:e078876.","journal-title":"BMJ (Clinical Res ed)"},{"issue":"15","key":"16084_CR23","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1001\/jama.2024.28463","volume":"333","author":"X Zhang","year":"2025","unstructured":"Zhang X, Wang J, Wang G, Zhang Y, Fan Q, Lu C, et al. First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer: The GEMSTONE-303 Randomized Clinical Trial. JAMA. 2025;333(15):1305\u201314.","journal-title":"JAMA"},{"issue":"12","key":"16084_CR24","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.clon.2024.09.007","volume":"36","author":"MS Beshr","year":"2024","unstructured":"Beshr MS, Beshr IA, Al Hayek M, Alfaqaih SM, Abuajamieh M, Basheer E, et al. PD-1\/PD-L1 Inhibitors in Combination With Chemo or as Monotherapy vs. Chemotherapy Alone in Advanced, Unresectable HER2-Negative Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: A Meta-Analysis. Clin Oncol (R Coll Radiol). 2024;36(12):797\u2013808.","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"16084_CR25","doi-asserted-by":"crossref","unstructured":"Zhang W, Guo K, Zheng S. Immunotherapy combined with chemotherapy in the first-line treatment of advanced gastric cancer: systematic review and Bayesian network meta-analysis based on specific PD-L1 CPS. Curr Oncol. 2025;32(2):112.","DOI":"10.3390\/curroncol32020112"},{"key":"16084_CR26","doi-asserted-by":"publisher","first-page":"1564604","DOI":"10.3389\/fimmu.2025.1564604","volume":"16","author":"Y Lin","year":"2025","unstructured":"Lin Y, Liao Y, Shen J. First-line immune checkpoint inhibitors with chemotherapy in advanced gastric and gastroesophageal junction adenocarcinoma: a meta-analysis of phase 3 trials. Front Immunol. 2025;16:1564604.","journal-title":"Front Immunol"},{"key":"16084_CR27","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","volume":"16","author":"S Bagchi","year":"2021","unstructured":"Bagchi S, Yuan R, Engleman EG. Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance. Annu Rev Pathol. 2021;16:223\u201349.","journal-title":"Annu Rev Pathol"},{"key":"16084_CR28","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.bioactmat.2024.09.024","volume":"43","author":"Y Guo","year":"2025","unstructured":"Guo Y, Wang Z, Li G, Zhan M, Xiao T, Wang J, et al. A polymer nanogel-based therapeutic nanovaccine for prophylaxis and direct treatment of tumors via a full-cycle immunomodulation. Bioactive Mater. 2025;43:129\u201344.","journal-title":"Bioactive Mater"},{"issue":"2","key":"16084_CR29","doi-asserted-by":"publisher","first-page":"100128","DOI":"10.59717\/j.xinn-med.2025.100128","volume":"3","author":"Z Xiao","year":"2025","unstructured":"Xiao Z, Wang J, Yang J, Guo F, Zhang L, Zhang L. Dendritic cells instruct T cell anti-tumor immunity and immunotherapy response. Innov Med. 2025;3(2):100128.","journal-title":"Innov Med"},{"key":"16084_CR30","doi-asserted-by":"crossref","unstructured":"Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol. 2008;8:59\u201373.","DOI":"10.1038\/nri2216"},{"issue":"1","key":"16084_CR31","doi-asserted-by":"publisher","first-page":"2447403","DOI":"10.1080\/07853890.2024.2447403","volume":"57","author":"G Li","year":"2025","unstructured":"Li G, Che X, Wang S, Liu D, Xie D, Jiang B, et al. The role of cisplatin in modulating the tumor immune microenvironment and its combination therapy strategies: a new approach to enhance anti-tumor efficacy. Ann Med. 2025;57(1):2447403.","journal-title":"Ann Med"},{"issue":"2","key":"16084_CR32","doi-asserted-by":"publisher","first-page":"537","DOI":"10.7150\/ijbs.89080","volume":"20","author":"W Xuzhang","year":"2024","unstructured":"Xuzhang W, Lu T, Jin W, Yu Y, Li Z, Shen L, et al. Cisplatin-induced Pyroptosis Enhances the Efficacy of PD-L1 Inhibitor in Small-Cell Lung Cancer via GSDME\/IL12\/CD4Tem Axis. Int J Biol Sci. 2024;20(2):537\u201353.","journal-title":"Int J Biol Sci"},{"key":"16084_CR33","doi-asserted-by":"publisher","first-page":"568931","DOI":"10.3389\/fimmu.2020.568931","volume":"11","author":"K Hudson","year":"2020","unstructured":"Hudson K, Cross N, Jordan-Mahy N, Leyland R. The Extrinsic and Intrinsic Roles of PD-L1 and Its Receptor PD-1: Implications for Immunotherapy Treatment. Front Immunol. 2020;11:568931.","journal-title":"Front Immunol"},{"issue":"26","key":"16084_CR34","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443\u201354.","journal-title":"N Engl J Med"},{"issue":"3","key":"16084_CR35","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1001\/jamaoncol.2019.5367","volume":"6","author":"J Duan","year":"2020","unstructured":"Duan J, Cui L, Zhao X, Bai H, Cai S, Wang G, et al. Use of immunotherapy with programmed cell death 1 vs programmed cell death ligand 1 inhibitors in patients with cancer: a systematic review and meta-analysis. JAMA Oncol. 2020;6(3):375\u201384.","journal-title":"JAMA Oncol"},{"issue":"4","key":"16084_CR36","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1038\/s41591-024-03450-4","volume":"31","author":"L Shen","year":"2025","unstructured":"Shen L, Zhang Y, Li Z, Zhang X, Gao X, Liu B, et al. First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial. Nat Med. 2025;31(4):1163\u201370.","journal-title":"Nat Med"},{"issue":"10","key":"16084_CR37","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/S1470-2045(23)00411-4","volume":"24","author":"X Gao","year":"2023","unstructured":"Gao X, Xu N, Li Z, Shen L, Ji K, Zheng Z, et al. Safety and antitumour activity of cadonilimab, an anti-PD-1\/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b\/2 trial. Lancet Oncol. 2023;24(10):1134\u201346.","journal-title":"Lancet Oncol"},{"issue":"1","key":"16084_CR38","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s12876-025-03754-w","volume":"25","author":"X Ji","year":"2025","unstructured":"Ji X, Wang G, Pan D, Xu S, Lei X. Efficacy and safety of pembrolizumab in advanced gastric and gastroesophageal junction cancer: a systematic review and meta-analysis. BMC Gastroenterol. 2025;25(1):173.","journal-title":"BMC Gastroenterol"},{"key":"16084_CR39","doi-asserted-by":"publisher","first-page":"1566939","DOI":"10.3389\/fimmu.2025.1566939","volume":"16","author":"W Pu","year":"2025","unstructured":"Pu W, Li S, Zhang J, Huang J, Li J, Jiang Y, et al. The efficacy and safety of PD-1\/PD-L1 inhibitors in combination with chemotherapy as a first-line treatment for unresectable, locally advanced, HER2-negative gastric or gastroesophageal junction cancer: a meta-analysis of randomized controlled trials. Front Immunol. 2025;16:1566939.","journal-title":"Front Immunol"},{"issue":"5","key":"16084_CR40","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1001\/jamaoncol.2020.7684","volume":"7","author":"C Valero","year":"2021","unstructured":"Valero C, Lee M, Hoen D, Zehir A, Berger MF, Seshan VE, et al. Response Rates to Anti-PD-1 Immunotherapy in Microsatellite-Stable Solid Tumors With 10 or More Mutations per Megabase. JAMA Oncol. 2021;7(5):739\u201343.","journal-title":"JAMA Oncol"},{"issue":"1","key":"16084_CR41","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1038\/s41392-023-01622-1","volume":"8","author":"MZ Qiu","year":"2023","unstructured":"Qiu MZ, Wang C, Wu Z, Zhao Q, Zhao Z, Huang CY, et al. Dynamic single-cell mapping unveils Epstein\u2013Barr virus-imprinted T-cell exhaustion and on-treatment response. Signal Transduct Target therapy. 2023;8(1):370.","journal-title":"Signal Transduct Target therapy"},{"key":"16084_CR42","doi-asserted-by":"publisher","first-page":"175883592312179","DOI":"10.1177\/17588359231217967","volume":"16","author":"Y Kubota","year":"2024","unstructured":"Kubota Y, Shitara K. Zolbetuximab for Claudin18.2-positive gastric or gastroesophageal junction cancer. Ther Adv Med Oncol. 2024;16:17588359231217967.","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"16084_CR43","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1186\/s12916-022-02421-1","volume":"20","author":"K Jia","year":"2022","unstructured":"Jia K, Chen Y, Sun Y, Hu Y, Jiao L, Ma J, et al. Multiplex immunohistochemistry defines the tumor immune microenvironment and immunotherapeutic outcome in CLDN18.2-positive gastric cancer. BMC Med. 2022;20(1):223.","journal-title":"BMC Med"},{"issue":"1","key":"16084_CR44","doi-asserted-by":"publisher","first-page":"100762","DOI":"10.1016\/j.esmoop.2022.100762","volume":"8","author":"Y Kubota","year":"2023","unstructured":"Kubota Y, Kawazoe A, Mishima S, Nakamura Y, Kotani D, Kuboki Y, et al. Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer. ESMO Open. 2023;8(1):100762.","journal-title":"ESMO Open"},{"key":"16084_CR45","doi-asserted-by":"publisher","first-page":"905651","DOI":"10.3389\/fimmu.2022.905651","volume":"13","author":"X Guo","year":"2022","unstructured":"Guo X, Yang B, He L, Sun Y, Song Y, Qu X. PD-1 inhibitors plus oxaliplatin or cisplatin-based chemotherapy in first-line treatments for advanced gastric cancer: A network meta-analysis. Front Immunol. 2022;13:905651.","journal-title":"Front Immunol"},{"issue":"1","key":"16084_CR46","doi-asserted-by":"publisher","first-page":"22024","DOI":"10.1038\/s41598-022-24426-9","volume":"12","author":"S Liu","year":"2022","unstructured":"Liu S, Wong HY, Xie L, Kim Y, Shu D, Zheng B, et al. Comparative efficacy and tolerability of targeted and immunotherapy combined with chemotherapy as first-line treatment for advanced gastric cancer: a Bayesian network meta-analysis. Sci Rep. 2022;12(1):22024.","journal-title":"Sci Rep"},{"issue":"4","key":"16084_CR47","doi-asserted-by":"publisher","first-page":"290","DOI":"10.21037\/atm-20-6639","volume":"9","author":"S Pan","year":"2021","unstructured":"Pan S, Li K, Huang B, Huang J, Xu H, Zhu Z. Efficacy and safety of immune checkpoint inhibitors in gastric cancer: a network meta-analysis of well-designed randomized controlled trials. Annals translational Med. 2021;9(4):290.","journal-title":"Annals translational Med"},{"key":"16084_CR48","doi-asserted-by":"publisher","first-page":"175883592412312","DOI":"10.1177\/17588359241231253","volume":"16","author":"Z Zhang","year":"2024","unstructured":"Zhang Z, Xie T, Wang Y, Shen L, Zhang X, Peng Z. Immune checkpoint inhibitors or anti-claudin 18.2 antibodies? A network meta-analysis for the optimized first-line therapy of HER2-negative gastric cancer. Therapeutic Adv Med Oncol. 2024;16:17588359241231253.","journal-title":"Therapeutic Adv Med Oncol"},{"issue":"10418","key":"16084_CR49","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1016\/S0140-6736(23)02033-0","volume":"402","author":"YY Janjigian","year":"2023","unstructured":"Janjigian YY, Kawazoe A, Bai Y, Xu J, Lonardi S, Metges JP, et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. Lancet. 2023;402(10418):2197\u2013208.","journal-title":"Lancet"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16084-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16084-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16084-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T10:02:21Z","timestamp":1782727341000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16084-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,6]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16084"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16084-1","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,6]]},"assertion":[{"value":"4 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"780"}}